Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Bunya Virus Infection Market

ID: MRFR/HC/33494-HCR
100 Pages
Rahul Gotadki
Last Updated: May 18, 2026

Bunya Virus Infection Market Research Report By Transmission Route (Vector-Borne, Airborne, Direct Contact), By Product Type (Vaccines, Antiviral Drugs, Diagnostic Tests), By End User (Hospitals, Diagnostic Laboratories, Research Institutions), By Treatment Method (Supportive Care, Antiviral Therapy, Immunotherapy) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Bunya Virus Infection Market Infographic
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Billion)
      1. 4.1.1 Clinical Diagnosis
      2. 4.1.2 Research and Development
      3. 4.1.3 Vaccine Development
      4. 4.1.4 Public Health Surveillance
    2. 4.2 Healthcare, BY End Use (USD Billion)
      1. 4.2.1 Hospitals
      2. 4.2.2 Diagnostic Laboratories
      3. 4.2.3 Research Institutions
      4. 4.2.4 Government Health Agencies
    3. 4.3 Healthcare, BY Transmission Route (USD Billion)
      1. 4.3.1 Vector-Borne
      2. 4.3.2 Zoonotic
      3. 4.3.3 Human-to-Human
      4. 4.3.4 Environmental
    4. 4.4 Healthcare, BY Type of Bunya Virus (USD Billion)
      1. 4.4.1 Crimean-Congo Hemorrhagic Fever Virus
      2. 4.4.2 Hantavirus
      3. 4.4.3 Nairovirus
      4. 4.4.4 Phlebovirus
    5. 4.5 Healthcare, BY Region (USD Billion)
      1. 4.5.1 North America
        1. 4.5.1.1 US
        2. 4.5.1.2 Canada
      2. 4.5.2 Europe
        1. 4.5.2.1 Germany
        2. 4.5.2.2 UK
        3. 4.5.2.3 France
        4. 4.5.2.4 Russia
        5. 4.5.2.5 Italy
        6. 4.5.2.6 Spain
        7. 4.5.2.7 Rest of Europe
      3. 4.5.3 APAC
        1. 4.5.3.1 China
        2. 4.5.3.2 India
        3. 4.5.3.3 Japan
        4. 4.5.3.4 South Korea
        5. 4.5.3.5 Malaysia
        6. 4.5.3.6 Thailand
        7. 4.5.3.7 Indonesia
        8. 4.5.3.8 Rest of APAC
      4. 4.5.4 South America
        1. 4.5.4.1 Brazil
        2. 4.5.4.2 Mexico
        3. 4.5.4.3 Argentina
        4. 4.5.4.4 Rest of South America
      5. 4.5.5 MEA
        1. 4.5.5.1 GCC Countries
        2. 4.5.5.2 South Africa
        3. 4.5.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 CSL Limited (AU)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Emergent BioSolutions (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Takeda Pharmaceutical Company Limited (JP)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bavarian Nordic (DK)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Valneva SE (FR)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Vaxart, Inc. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Inovio Pharmaceuticals, Inc. (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 AstraZeneca PLC (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY APPLICATION
    4. 6.4 US MARKET ANALYSIS BY END USE
    5. 6.5 US MARKET ANALYSIS BY TRANSMISSION ROUTE
    6. 6.6 US MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    7. 6.7 CANADA MARKET ANALYSIS BY APPLICATION
    8. 6.8 CANADA MARKET ANALYSIS BY END USE
    9. 6.9 CANADA MARKET ANALYSIS BY TRANSMISSION ROUTE
    10. 6.10 CANADA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    11. 6.11 EUROPE MARKET ANALYSIS
    12. 6.12 GERMANY MARKET ANALYSIS BY APPLICATION
    13. 6.13 GERMANY MARKET ANALYSIS BY END USE
    14. 6.14 GERMANY MARKET ANALYSIS BY TRANSMISSION ROUTE
    15. 6.15 GERMANY MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    16. 6.16 UK MARKET ANALYSIS BY APPLICATION
    17. 6.17 UK MARKET ANALYSIS BY END USE
    18. 6.18 UK MARKET ANALYSIS BY TRANSMISSION ROUTE
    19. 6.19 UK MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    20. 6.20 FRANCE MARKET ANALYSIS BY APPLICATION
    21. 6.21 FRANCE MARKET ANALYSIS BY END USE
    22. 6.22 FRANCE MARKET ANALYSIS BY TRANSMISSION ROUTE
    23. 6.23 FRANCE MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    24. 6.24 RUSSIA MARKET ANALYSIS BY APPLICATION
    25. 6.25 RUSSIA MARKET ANALYSIS BY END USE
    26. 6.26 RUSSIA MARKET ANALYSIS BY TRANSMISSION ROUTE
    27. 6.27 RUSSIA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    28. 6.28 ITALY MARKET ANALYSIS BY APPLICATION
    29. 6.29 ITALY MARKET ANALYSIS BY END USE
    30. 6.30 ITALY MARKET ANALYSIS BY TRANSMISSION ROUTE
    31. 6.31 ITALY MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    32. 6.32 SPAIN MARKET ANALYSIS BY APPLICATION
    33. 6.33 SPAIN MARKET ANALYSIS BY END USE
    34. 6.34 SPAIN MARKET ANALYSIS BY TRANSMISSION ROUTE
    35. 6.35 SPAIN MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    36. 6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    37. 6.37 REST OF EUROPE MARKET ANALYSIS BY END USE
    38. 6.38 REST OF EUROPE MARKET ANALYSIS BY TRANSMISSION ROUTE
    39. 6.39 REST OF EUROPE MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    40. 6.40 APAC MARKET ANALYSIS
    41. 6.41 CHINA MARKET ANALYSIS BY APPLICATION
    42. 6.42 CHINA MARKET ANALYSIS BY END USE
    43. 6.43 CHINA MARKET ANALYSIS BY TRANSMISSION ROUTE
    44. 6.44 CHINA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    45. 6.45 INDIA MARKET ANALYSIS BY APPLICATION
    46. 6.46 INDIA MARKET ANALYSIS BY END USE
    47. 6.47 INDIA MARKET ANALYSIS BY TRANSMISSION ROUTE
    48. 6.48 INDIA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    49. 6.49 JAPAN MARKET ANALYSIS BY APPLICATION
    50. 6.50 JAPAN MARKET ANALYSIS BY END USE
    51. 6.51 JAPAN MARKET ANALYSIS BY TRANSMISSION ROUTE
    52. 6.52 JAPAN MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    53. 6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    54. 6.54 SOUTH KOREA MARKET ANALYSIS BY END USE
    55. 6.55 SOUTH KOREA MARKET ANALYSIS BY TRANSMISSION ROUTE
    56. 6.56 SOUTH KOREA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    57. 6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION
    58. 6.58 MALAYSIA MARKET ANALYSIS BY END USE
    59. 6.59 MALAYSIA MARKET ANALYSIS BY TRANSMISSION ROUTE
    60. 6.60 MALAYSIA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    61. 6.61 THAILAND MARKET ANALYSIS BY APPLICATION
    62. 6.62 THAILAND MARKET ANALYSIS BY END USE
    63. 6.63 THAILAND MARKET ANALYSIS BY TRANSMISSION ROUTE
    64. 6.64 THAILAND MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    65. 6.65 INDONESIA MARKET ANALYSIS BY APPLICATION
    66. 6.66 INDONESIA MARKET ANALYSIS BY END USE
    67. 6.67 INDONESIA MARKET ANALYSIS BY TRANSMISSION ROUTE
    68. 6.68 INDONESIA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    69. 6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION
    70. 6.70 REST OF APAC MARKET ANALYSIS BY END USE
    71. 6.71 REST OF APAC MARKET ANALYSIS BY TRANSMISSION ROUTE
    72. 6.72 REST OF APAC MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    73. 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. 6.74 BRAZIL MARKET ANALYSIS BY APPLICATION
    75. 6.75 BRAZIL MARKET ANALYSIS BY END USE
    76. 6.76 BRAZIL MARKET ANALYSIS BY TRANSMISSION ROUTE
    77. 6.77 BRAZIL MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    78. 6.78 MEXICO MARKET ANALYSIS BY APPLICATION
    79. 6.79 MEXICO MARKET ANALYSIS BY END USE
    80. 6.80 MEXICO MARKET ANALYSIS BY TRANSMISSION ROUTE
    81. 6.81 MEXICO MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    82. 6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION
    83. 6.83 ARGENTINA MARKET ANALYSIS BY END USE
    84. 6.84 ARGENTINA MARKET ANALYSIS BY TRANSMISSION ROUTE
    85. 6.85 ARGENTINA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
    88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY TRANSMISSION ROUTE
    89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    90. 6.90 MEA MARKET ANALYSIS
    91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY END USE
    93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY TRANSMISSION ROUTE
    94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY END USE
    97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY TRANSMISSION ROUTE
    98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    99. 6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION
    100. 6.100 REST OF MEA MARKET ANALYSIS BY END USE
    101. 6.101 REST OF MEA MARKET ANALYSIS BY TRANSMISSION ROUTE
    102. 6.102 REST OF MEA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
    103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. 6.104 RESEARCH PROCESS OF MRFR
    105. 6.105 DRO ANALYSIS OF HEALTHCARE
    106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. 6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    110. 6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    111. 6.111 HEALTHCARE, BY END USE, 2024 (% SHARE)
    112. 6.112 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
    113. 6.113 HEALTHCARE, BY TRANSMISSION ROUTE, 2024 (% SHARE)
    114. 6.114 HEALTHCARE, BY TRANSMISSION ROUTE, 2024 TO 2035 (USD Billion)
    115. 6.115 HEALTHCARE, BY TYPE OF BUNYA VIRUS, 2024 (% SHARE)
    116. 6.116 HEALTHCARE, BY TYPE OF BUNYA VIRUS, 2024 TO 2035 (USD Billion)
    117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.2.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.2.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.2.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.3.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.3.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.3.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.4.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.4.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.4.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.5.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.5.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.5.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.6.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.6.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.6.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.7.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.7.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.7.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.8.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.8.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.8.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.9.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.9.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.9.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.10.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.10.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.10.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.11.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.11.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.11.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.12.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.12.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.12.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.13.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.13.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.13.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.14.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.14.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.14.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.15.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.15.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.15.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.16.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.16.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.16.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.17.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.17.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.17.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.18.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.18.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.18.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.19.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.19.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.19.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.20.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.20.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.20.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.21.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.21.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.21.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.22.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.22.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.22.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.23.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.23.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.23.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.24.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.24.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.24.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.25.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.25.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.25.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.26.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.26.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.26.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.27.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.27.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.27.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.28.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.28.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.28.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.29.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.29.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.29.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY APPLICATION, 2025-2035 (USD Billion)
      2. 7.30.2 BY END USE, 2025-2035 (USD Billion)
      3. 7.30.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      4. 7.30.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2025-2035)

  • Clinical Diagnosis
  • Research and Development
  • Vaccine Development
  • Public Health Surveillance

Healthcare By End Use (USD Billion, 2025-2035)

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutions
  • Government Health Agencies

Healthcare By Transmission Route (USD Billion, 2025-2035)

  • Vector-Borne
  • Zoonotic
  • Human-to-Human
  • Environmental

Healthcare By Type of Bunya Virus (USD Billion, 2025-2035)

  • Crimean-Congo Hemorrhagic Fever Virus
  • Hantavirus
  • Nairovirus
  • Phlebovirus

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓